Long-term management of plaque psoriasis with continuous efalizumab therapy - 09/08/11
Doi : 10.1016/j.jaad.2005.10.028
Alan Menter, MD a, ⁎ 
, Craig L. Leonardi, MD b, Wolfram Sterry, MD c, Jan D. Bos, MD d, Kim A. Papp, MD, PhD e
, Craig L. Leonardi, MD b, Wolfram Sterry, MD c, Jan D. Bos, MD d, Kim A. Papp, MD, PhD e a From Baylor University Medical Center, Dallas
b St. Louis University School of Medicine
c University Hospital Charité Berlin
d Academic Medical Center, University of Amsterdam
e Probity Medical Research, Waterloo
Reprint requests: Alan Menter, MD, Texas Dermatology Research Institute, 5310 Harvest Hill Rd, Suite 260, Dallas, TX 75230.Dallas, Texas; St. Louis, Missouri; Berlin, Germany; Amsterdam, The Netherlands; and Waterloo, Ontario, Canada
Abbreviations used : GIF, LMB, PASI, PASI-50, PASI-75
Plan
| Supported by Genentech Inc and Serono International SA. Disclosures: Dr Leonardi has received educational grant support from and served on the speakers bureau and advisory board for Genentech Inc. Dr Menter has received research support and/or is a consultant and/or lecturer for Abbott Laboratories, Amgen Inc, Biogen Idec, Centocor Inc, Genentech Inc, Serono SA, and Xoma LLC. Dr Papp is a consultant, an investigator, and an advisory board member for Genentech Inc, Serono SA, and Xoma LLC; he is on the Serono SA speakers bureau. Drs Bos and Sterry have no conflicts of interest to disclose. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 4S
P. S182-S188 - avril 2006 Retour au numéro
Article précédent
- Relapse, rebound, and psoriasis adverse events: An advisory group report
- Wayne Carey, Scott Glazer, Alice B. Gottlieb, Mark Lebwohl, Craig Leonardi, Alan Menter, Kim Papp, Amy Chen Rundle, Darryl Toth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?